19:51 , Aug 10, 2018 |  BioCentury  |  Finance

Sound story

Preclinical data supporting Akouos Inc.’s hearing loss program convinced 5AM Ventures to re-up for a $50 million series A round, and those funds plus additions to the Akouos team have the company poised to take...
18:40 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Hearing loss play Akouos grabs $50M series A

Akouos Inc. (Boston, Mass.) raised $50 million on Aug. 7 in a series A round co-led by existing investors 5AM Ventures and New Enterprise Associates. Partners Innovation Fund and new investors Sofinnova Ventures, RA Capital...
11:03 , Aug 7, 2018 |  BC Extra  |  Financial News

Hearing loss play Akouos grabs $50M series A

Akouos Inc. (Boston, Mass.) raised $50 million in a series A round co-led by existing investors 5AM Ventures and New Enterprise Associates. Partners Innovation Fund and new investors Sofinnova Ventures, RA Capital Management and Novartis...
02:53 , Dec 8, 2017 |  BC Week In Review  |  Company News

Akouos licenses gene therapy tech from Massachusetts Eye and Ear

Newco Akouos Inc. (Boston, Mass.) acquired an exclusive license to a vector platform from Massachusetts Eye and Ear (Boston, Mass.) and Lonza Group Ltd. (SIX:LONN) to develop gene therapies for hearing and balance disorders. The...
22:19 , Dec 1, 2017 |  BC Extra  |  Company News

Akouos in-licenses gene therapy vectors from Mass. Eye and Ear

Newco Akouos Inc. (Boston, Mass.) acquired an exclusive license to a vector platform to develop gene therapies for hearing and balance disorders from Massachusetts Eye and Ear (Boston, Mass.) and Lonza Group Ltd. (SIX:LONN). The...